Oric Pharmaceuticals Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy
Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech
ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd half of 2025 and a phase 3 trial to start in 2026. ORIC-944 in combination with ERLEADA and/or NUBEQ is being tested for the treatment of patients with metastatic castration-resistant prostate cancer; Data readouts from dose-optimization cohorts expected in 2025. The global prostate cancer market is expected to reach $29.2 billion by 2035; Approximately between 10% to 20% of all prostate cancers are as classified as castration-resistant.
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals NASDAQ: ORIC is a small-cap pharma stock. It aims to make a difference with its potentially "best-in-class" treatments.
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
ORIC Pharmaceuticals, Inc. expects updated results from the phase 1b study, using ORIC-114 for the treatment of patients with mutated NSCLC, in the 1st half of 2025. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; Still a good market opportunity to go after, even if only targeting mutant NSCLC patients. Collaboration supply agreements made with J&J and Bayer to advance ORIC-944 in combination with ERLEADA and NUBEQA for treatment of patients with mCRPC respectively.
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
